|
#1
07.05.2005, 09:12
|
|||
|
|||
|
Äåðìàòîëîãèÿ, êîñìåòîëîãèÿ, îáëûñåíèå
Äåðìàòîëîãèÿ, êîñìåòîëîãèÿ, îáëûñåíèå
|
|
#2
07.05.2005, 15:43
|
|||
|
|||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Online book of dermatology and venerology
|
|
#3
07.05.2005, 18:34
|
|||
|
|||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Àìåðèêàíñêàÿ àêàäåìèÿ äåðìàòîëîãèè. Æóðíàë, äîñòóïíû àáñòðàêòû
|
|
#4
12.05.2005, 18:34
|
|||
|
|||
|
«Îöåíêà êà÷åñòâà æèçíè â äåðìàòîëîãèè» (íà àíãë. ÿç.)
Íà ïðîòÿæåíèè äâóõ äåñÿòèëåòèé ôàêóëüòåò äåðìàòîëîãèè Óýëüñêîãî ìåäèöèíñêîãî êîëëåäæà Êàðäèôôñêîãî óíèâåðñèòåòà èãðàåò âàæíóþ ðîëü â ðàçðàáîòêå è àòòåñòàöèè èçìåðåíèé îöåíêè êà÷åñòâà æèçíè, ïðåäíàçíà÷åííûõ äëÿ èñïîëüçîâàíèÿ â äåðìàòîëîãèè. Âåá-ñàéò ïðåäñòàâëÿåò êëþ÷åâûå ìåðû îöåíêè êà÷åñòâà æèçíè, ðàçðàáîòàííûå ýòèì àâòîðñêèì êîëëåêòèâîì. Äëÿ êàæäîé ìåðû ïðèâåäåíî ïîëíîå îïèñàíèå, ïåðåâîäû, èíñòðóêöèè è ññûëêè íà èõ èñïîëüçîâàíèå. Äàííûé ðåñóðñ ìîæåò èñïîëüçîâàòüñÿ êëèíèöèñòàìè â îáû÷íîé êëèíè÷åñêîé ïðàêòèêå äëÿ ñîäåéñòâèÿ êëèíè÷åñêèì êîíñóëüòàöèÿì, îöåíêå è ïðèíÿòèþ êëèíè÷åñêèõ ðåøåíèé. Ñïåöèàëüíîãî ðàçðåøåíèÿ äëÿ ýòîãî íå òðåáóåòñÿ, è ïëàòà çà èñïîëüçîâàíèå óêàçàííîãî ðåñóðñà â äàííîì êîíòåêñòå íå âçèìàåòñÿ. Îäíàêî ñóùåñòâóåò òðåáîâàíèå î òîì, ÷òîáû â êîíöå êàæäîãî ýêçåìïëÿðà èñïîëüçóåìîãî ìàòåðèàëà íà ëþáîì ÿçûêå îáÿçàòåëüíî áûëî ïðèâåäåíî óêàçàíèå î çàùèòå àâòîðñêèõ ïðàâ. URL: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#5
01.06.2005, 12:57
|
|||
|
|||
|
Atlas of dermatology
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#6
11.08.2005, 18:19
|
|||
|
|||
|
Äèàãíîñòèêà è ëå÷åíèå ïåäèêóëåçà è ÷åñîòêè
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] __________________ ßíà Ñòóäåíöîâà
|
|
#7
08.12.2005, 14:37
|
|||
|
|||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Clinical Guidelines
|
|
|
|
#8
09.03.2006, 18:39
|
|||
|
|||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
The Electronic Textbook of Dermatology. Rhett Drugge, M.D. New York University 1995-200 îí-ëàéí
|
|
#9
04.04.2006, 19:54
|
||||
|
||||
|
Êîëëåêöèÿ àòëàñîâ ïî äåðìàòîâåíåðîëîãèè
Atlas of Clinical Dermatology
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Íåïëîõîé àòëàñ ïî äåðìàòîëîãèè (Danish) ÀâòîðûNiels K.Veien,MD;Mads Nielsen,MD Danish national service on dermato-venereology Clinical Images-Genital/Rectal Images [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ïîðàæåíèå â àíîãåíèòàëüíîé îáëàñòè ïðè áîëåçíÿõ êîæè,ïîëîâûõ èíôåêöèÿõ è äðóãèõ çàáîëåâàíèÿõ. University of California.Charlie Goldberg, M.D. Moulages museum [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ìóëÿæè,÷åðíî-áåëûå ôîòîãðàôèè êîæíûõ è âåíåðè÷åñêèõ áîëåçíåé îò Ìóçåÿ ìóëÿæåé (Paris,FR) Dermatopathology Review [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Êîëëåêöèÿ äåðìàòîëîãè÷åñêèõ èçîáðàæåíèé îò Univ of Texas/Houston Medical School (US) Dermatology Collection [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Äåðìàòîëîãè÷åñêèé àòëàñ îò Health Education Assets Library Dermatopathology [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Äåðìàòîëîãè÷åñêèé àòëàñ îò Cornell University Medical College Nomenclature of Skin Lesions [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Developed by Gary Williams, M.D. and Murray Katcher, M.D. Ph.D, Department of Pediatrics with funding and support from the Wisconsin Area Health Education Center (AHEC) System Àòëàñ ïåðâè÷íûõ è âòîðè÷íûõ ýëåìåíòîâ ïðè çàáîëåâàíèÿõ êîæè.Î÷åíü öåíåí äëÿ ñòóäåíòîâ Clinical Images of the Skin [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Äåðìàòîëîãè÷åñêèé àòëàñ îò University of California. Àâòîð Charlie Goldberg, M.D. Atlas de Dermatologie du Pr. M. Heenen [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Àòëàñ ïî äåðìàòîëîãèè le professeur M. Heenen (Áðþññåëü) 2001 Skin Tumor Atlas [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Àòëàñ ïî äåðìàòîîíêîëîãèè-Basal Cell Carcinoma,Squamous Cell Carcinoma,Melanoma. Atlas Virtual de Dermatología de Panamá [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Àòëàñ âèðòóàëüíîé äåðìàòîëîãèè (Ïàíàìà)- î÷åíü ïîäðîáíî î òðîïè÷åñêèõ äåðìàòîçàõ + îñòàëüíûå äåðìàòîçû è STD Dermatology Database [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Àòëàñ ïî äåðìàòîâåíåðîëîãèè.Ñëîâåíèÿ (English) On-line Atlas of Dermatology and Rheumatology [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] The On-line ATLAS is a collection of images of peculiar cutaneous manifestations of rheumatic diseases and is dedicated to students and medical practitioners working in the field of Dermatology and Rheumatology DermIS.net [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] DermIS.net is the largest dermatology information service available on the internet. It offers elaborate image atlases complete with diagnoses and differential diagnoses, case reports and additional information on almost all skin diseases Áûâøèé çíàìåíèòûé DOIA - Dermatology Images Online Atlas Global Skin Atlas [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] The International Atlas of Dermatology and Dermatopathology is a joint effort of Doctors in various countries to cover the spectrum of skin disease in all skin colours and races. The images may be freely used for self education and for teaching purposes but may not be used in any other medium without permission from the editors. Dermnet.com [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Dermatologists' image resource Dermatology Slide Atlas [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] University of North Carolina School of Medicine Atlas de Dermatologia General [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Prof.J. de Olavide 1873 - ïîýòîìó ðèñîâàííûé è íà èñïàíñêîì ÿçûêå Dermatology atlas [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Samuel Freire da Silva, M.D. (íà èñïàíñêîì ÿçûêå).Î÷åíü õîðîøèé àòëàñ. Interactive Dermatology Atlas [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Richard P. Usatine, M.D. Brian D. Madden, M.D. Dermatology Image Bank [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Spenser S. Eeeles Health Seiences Library Dermatology Atlas [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Loyola University Dermatology Medical Education Website Dermatlas.org [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Dermatology Image Atlas. 6268 IMAGES and 222 contributors dermatlogy links ( íàñòîÿùèé ìîìåíò óæå áîëüøå) Atlas de dermatologia online [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Service de dermatologie CHU FARHAT HACHED SOUSSE TUNISIE (íà ôðàíöóçñêîì ÿçûêå) Dermatologic Image Database [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Dept.of Dermatology - University of Iowa College of Medicine Atlas of dermatology [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] The clinical part of the atlas (including clinical pictures) was supported by the grant from the fund for development of Czech universities (Czech ministry of education) Atlas de dermatologia [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Àòëàñ ïî äåðìàòîëîãèè íà èñïàíñêîì ÿçûêå.Àíàòîìèÿ,íàèáîëåå ÷àñòî âñòðå÷àþùèåñÿ çàáîëåâàíèÿ êîæè Dermatlas.RU [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Èíòåðíåò-ñàéò DermAtlas.RU - îòêðûòûé íåçàâèñèìûé ñåòåâîé ïðîåêò äèñòàíöèîííîãî îáðàçîâàíèÿ è ïîâûøåíèÿ êâàëèôèêàöèè âðà÷åé â îáëàñòè äåðìàòîëîãèè
|
|
#10
05.04.2006, 12:17
|
||||
|
||||
|
Ìîíîãðàôèÿ ïî äåòñêîé äåðìàòîëîãèè
Principles of Pediatric Dermatology
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Îñíîâû äåòñêîé äåðìàòîëîãèè. Online ìîíîãðàôèÿ DR. MAHMOUD HIJAZY 2000 ñ ìíîãî÷èñëåííûìè èëëþñòðàöèÿìè.
|
|
#11
12.04.2006, 19:06
|
||||
|
||||
|
Neonatal dermatology
Neonatal dermatology
Íåïëîõîé àòëàñ-ñïðàâî÷íèê ïî íåîíàòàëüíîé äåðìàòîëîãèè:äîáðîêà÷åñòâåííûå,èíôåêöèîííûå,ïèãìåí òíûå,ñîñóäèñòûå è äðóãèå ïîðàæåíèÿ. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#12
13.04.2006, 12:49
|
||||
|
||||
|
Æóðíàëû ïî äåðìàòîâåíåðîëîãèè (open access)
BMC Dermatology
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] BMC Dermatology is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of skin disorders, as well as related molecular genetics, pathophysiology, and epidemiology. Dermatology Times [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Æóðíàë,ïîñâÿùåííûé ñàìûì ïîñëåäíèì ìåäèöèíñêèì íîâîñòÿì äåðìàòîëîãèè è êîñìåòîëîãèè. Indian Journal of Dermatology, Venereology and Leprology [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Èíäèéñêèé æóðíàë äåðìàòîâåíåðîëîãèè è ëåïðîëîãèè Acta Dermatovenereologica [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Archives of Dermatology [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]) Archives of Dermatology åæåìåñÿ÷íûé ìåäèöèíñêèé æóðíàë American Medical Association.Åñòü ñòàòüè ñ îòêðûòûì äîñòóïîì Skin Therapy Letter [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] A Physician's Access to Dermatology Treatment Information.Åñòü ñòàòüè è îáçîðû ñ îòêðûòûì äîñòóïîì,íî â îñíîâíîì ÷åðåç ãîä ïîñëå îïóáëèêîâàíèÿ. The Internet Journal of Dermatology [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Èçäàåòñÿ íåäàâíî,íî çàòî ïîëíûé äîñòóï ê ñòàòüÿì Âõîäèò â ãðóïïó online æóðíàëîâ è ïóáëèêàöèé Internet Scientific Publications, LLC Cochrane Skin Group [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] The Cochrane Skin Group is a network of people from all over the world committed to producing and updating systematic reviews of clinical trials relating to skin conditions. Dermatology online journal [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] An open-access, refereed publication intended to meet reference and education needs of the international dermatology community
|
|
#13
12.07.2006, 13:27
|
|||
|
|||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Êëèíè÷åñêîå ðóêîâîäñòâî Acne management Institute for Clinical Systems Improvement (ICSI). Bloomington
|
|
#14
09.02.2007, 21:41
|
|||
|
|||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Seborrhoeic dermatitis
|
|
#15
28.02.2007, 10:43
|
|||
|
|||
|
Æóðíàë "Îöåíêà ìåäèöèíñêèõ òåõíîëîãèé"
ïîëíûé òåêàñò pdf [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Health Technol Assess. 2006 Nov;10(46):1-252. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R. Centre for Reviews and Dissemination, University of York, UK. OBJECTIVES: To evaluate the clinical effectiveness, safety, tolerability and cost-effectiveness of etanercept and efalizumab for the treatment of moderate to severe chronic plaque psoriasis. DATA SOURCES: Major electronic databases and several Internet resources were searched up to April 2004. REVIEW METHODS: Systematic reviews were undertaken of the efficacy, safety and economic reviews of etanercept and efalizumab. An existing systematic review of the efficacy and safety of other treatments was also updated. Economic models supplied by the manufacturers of etanercept and efalizumab were critiqued. An economic model was then developed of etanercept and efalizumab in the treatment of moderate to severe chronic plaque psoriasis. RESULTS: The review of the clinical evidence identified a total of 39 published and three unpublished studies: eight randomised controlled trials (RCTs) of the efficacy of etanercept (three trials) and efalizumab (five); 10 studies of the adverse effects of the interventions; and 24 RCTs of the efficacy of the other treatments for moderate to severe psoriasis. The trials of the efficacy of the interventions were all double-blind and placebo-controlled trials and generally of good quality, but three of the five efalizumab trials were poorly reported. A total of 1347 patients were included in the etanercept trials and 2963 in the efalizumab trials. Data on the efficacy of etanercept 25 mg twice a week for 12 weeks were available from three RCTs. On average, active treatment resulted in 62% of patients achieving a Psoriasis Area and Severity Index (PASI) 50, 33% achieving a PASI 75, 11% achieving a PASI 90 and 40% were assessed as clear or almost clear. These figures are not adjusted for changes relative to placebo. Improvement in quality of life as assessed by mean percentage change in Dermatology Life Quality Index (DLQI) was around 59% with etanercept 25 mg twice a week compared with 9% with placebo, and all mean differences that could be calculated were statistically significantly in favour of etanercept. Data on the efficacy of etanercept 50 mg twice a week for 12 weeks were available from two RCTs. Across the two trials, the proportion of patients achieving PASI 50, 75 and 90 was 76, 49 and 21%, respectively; the pooled relative risks were all statistically significantly in favour of etanercept. The findings for mean PASI after treatment, mean percentage change in PASI from baseline and mean percentage change in DLQI also demonstrated the efficacy of etanercept treatment. Evidence from one RCT indicates that the response to etanercept is maintained post-treatment, at least in the medium term, and data from uncontrolled follow-up phases reflect and extend these findings. Efalizumab at a dose of 1 mg/kg once a week subcutaneously was studied in five RCTs. Across these trials, 12 weeks of active treatment resulted in an average of 55% of patients achieving PASI 50, 27% PASI 75, 4.3% PASI 90 and 27% clear or minimal psoriasis status. These figures are not adjusted for changes relative to placebo. There is no evidence from RCTs that the response to efalizumab 1 mg/kg once a week is maintained when treatment continues beyond 12 weeks, and long-term follow-up data relate to a range of doses and are poorly reported and so cannot be used to draw even tentative conclusions regarding the long-term efficacy of efalizumab. Uncontrolled data from trial follow-up suggest that time to relapse may be around 60 days. No data indicating the existence or absence of any rebound in psoriasis after discontinuation of efalizumab were identified. There is no evidence relating to the efficacy of efalizumab upon retreatment. A mixed treatment comparison analysis found a higher response rate in terms of PASI 50, 75 and 90 with etanercept than with efalizumab. Injection site reactions appear to be the most common adverse effects of etanercept. Overall, etanercept appears to be well tolerated in short- and long-term use, although many of the long-term data are not from patients with psoriasis. Headache, chills and, to a lesser extent, nausea, myalgia, pain and fever are the common adverse events associated with efalizumab. Overall, withdrawal rates due to adverse events are low. Longer term data for efalizumab are not readily available for evaluation, but the adverse events data up to 3 years appear to reflect those over 12 weeks and to remain stable. Unfortunately, few data for serious infections and serious adverse events with efalizumab are available. For the primary analysis comparing etanercept, efalizumab and supportive care, the results of the York Model suggest that the biological therapies would only be cost-effective for all patients with moderate to severe psoriasis if the NHS were willing to pay over pound60,000 per QALY gained. In patients with poor baseline quality of life (fourth quartile DLQI), efalizumab, etanercept 25 mg (intermittent), etanercept 25 mg (continuous) and etanercept 50 mg (intermittent) would be cost-effective as part of a treatment sequence if the NHS were willing to pay pound45,000, pound35,000, pound45,000 and pound65,000 per QALY gained, respectively. In patients who are also at high risk of inpatient hospitalisation (21 days per annum), these therapies would be cost-effective as part of a sequence as long as the NHS were willingness to pay pound25,000, pound20,000, pound25,000 and pound45,000 per QALY gained, respectively. As part of a secondary analysis including a wider range of systemic therapies as comparators, the York Model found that it would only be cost-effective to use etanercept and efalizumab in a sequence after methotrexate, ciclosporin and Fumaderm. CONCLUSIONS: Clinical trial data indicate that both etanercept and efalizumab are efficacious in patients who are eligible for systemic therapy, but the economic evaluation demonstrates that these biological therapies are likely to be cost-effective only in patients with poor baseline QoL and who are at risk of hospitalisation. Efficacy trials conducted in the specific population for which etanercept and efalizumab are licensed are required, as are long-term comparisons of etanercept and efalizumab with other treatments for moderate to severe psoriasis. Long-term efficacy trials and safety/tolerability data for patients treated with etanercept or efalizumab are required, as are trials on the response of specific subtypes of psoriasis to different drugs. Research on the rate of inpatient hospitalisation in patients with moderate to severe psoriasis is warranted, and the effect of treatment on this rate.
|
Ëèíåéíûé âèä
